The neurotoxicity of amphetamines: Bridging drugs of abuse and neurodegenerative disorders

Experimental Neurology

Volumn 201, Issue 1, 2006, Pages 24-31

  Iacovelli, Luisa ^a,b   Fulceri, Federica ^c   De Blasi, Antonio ^a   Nicoletti, Ferdinando ^a,d   Ruggieri, Stefano ^a,d   Fornai, Francesco ^a,c  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Synuclein; Arrestin; Amphetamines; Lewy body; MDMA; Methamphetamine; Neurodegenerative disorders; Neuronal inclusions; Parkinson's disease; Ubiquitin proteasome system

Indexed keywords

ALPHA SYNUCLEIN; AMPHETAMINE DERIVATIVE; BETA ARRESTIN; DOPAMINE; G PROTEIN COUPLED RECEPTOR; LEVODOPA; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITOR; MULTIENZYME COMPLEX; PARGYLINE; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN;

BASAL GANGLION; CATALYSIS; CENTRAL NERVOUS SYSTEM; DEGENERATION; DEGENERATIVE DISEASE; DRUG ABUSE; DRUG DEPENDENCE; HUMAN; IMMUNOREACTIVITY; LEWY BODY; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; ULTRASTRUCTURE;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; HUMANS; MODELS, NEUROLOGICAL; NEURODEGENERATIVE DISEASES; NEUROTOXICITY SYNDROMES; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 33747141059     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.02.130     Document Type: Review

References (57)

1. Battaglia G., Fornai F., Busceti C.L., Aloisi G., Cerrito F., De Blasi A., Melchiorri D., and Nicoletti F. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J. Neurosci. 22 (2002) 2135-2141
2. Bence N.F., Sampat R.M., and Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292 (2001) 1552-1555
3. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
4. Betarbet R., Sherer T.B., and Greenamyre J.T. Ubiquitin-proteasome system and Parkinson's diseases. Exp. Neurol. 191 (2005) S17-S27
5. Chuang T.T., Iacovelli L., Sallese M., and De Blasi A. G protein-coupled receptors: heterologous regulation of homologous desensitization and its implications. Trends Pharmacol. Sci. 17 (1996) 416-421
6. Chung K.K., Dawson V.L., and Dawson T.M. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci. 24 (2001) S7-S14
7. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury Jr. P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine alpha-synuclein adduct. Science 294 (2001) 1257-1258
8. Corti O., and Brice A. Parkinson's disease: what have we learned from the genes responsible for familial forms?. Med. Sci. (Paris) 19 (2003) 613-619
9. Cubells J.F., Rayport S., Rajendran G., and Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14 (1994) 2260-2271
10. De Blasi A., Capobianco L., Iacovelli L., Lenzi P., Ferrucci M., Lazzeri G., Fornai F., and Picascia A. Presence of beta-arrestin in cellular inclusions in metamphetamine-treated PC12 cells. Neurol. Sci. 24 (2003) 164-165
11. Deng X., Wang Y., Chou J., and Cadet J.L. Methamphetamine causes widespread apoptosis in the mouse brain: evidence from using an improved TUNEL histochemical method. Brain Res. Mol. Brain Res. 93 (2001) 64-69
12. Farrer M., Kachergus J., Forno L., Lincoln S., Wang D.S., Hulihan M., Maraganore D., Gwinn-Hardy K., Wszolek Z., Dickson D., and Langston J.W. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55 (2004) 174-179
13. Feany M.B., and Bender W.W. A Drosophila model of Parkinson's disease. Nature 404 (2000) 394-398
14. Fornai F., Lenzi P., Gesi M., Ferrucci M., Lazzeri G., Busceti C.L., Ruffoli R., Soldani P., Ruggieri S., Alessandri M.G., and Paparelli A. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 23 (2003) 8955-8966
15. Fornai F., Lenzi P., Frenzilli G., Gesi M., Ferrucci M., Lazzeri G., Biagioni F., Nigro M., Falleni A., Giusiani M., Pellegrini A., Blandini F., Ruggieri S., and Paparelli A. DNA damage and ubiquitinated neuronal inclusions in the substantia nigra and striatum of mice following MDMA (ecstasy). Psychopharmacology (Berlin) 173 (2004) 353-363
16. Fornai F., Lenzi P., Gesi M., Ferrucci M., Lazzeri G., Capobianco L., De Blasi A., Battaglia G., Nicoletti F., Ruggieri S., and Paparelli A. Similarities between methamphetamine toxicity and proteasome inhibition. Ann. N. Y. Acad. Sci. 1025 (2004) 1-9
17. Fornai F., Lenzi P., Gesi M., Soldani P., Ferrucci M., Lazzeri G., Capobianco L., Battaglia G., De Blasi A., Nicoletti F., and Paparelli A. Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J. Neurochem. 88 (2004) 114-123
18. Fornai F., Lenzi P., Ferrucci F., Lazzeri G., Bandettini di Poggio A., Natale G., Busceti C.L., Biagioni F., Giusiani M., Ruggier S., and Paparelli A. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. Brain Res. Bull. 65 (2005) 405-413
19. Fornai F., Schluter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti C.L., Pontarelli F., Battaglia G., Pellegrini A., Nicoletti F., Ruggieri S., Paparelli A., and Sudhof T.C. Parkinson-like sindrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and α-synuclein. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3413-3418
20. Fumagalli F., Gainetdinov R.R., Wang Y.M., Valenzano K.J., Miller G.W., and Caron M.G. Increased metamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 19 (1999) 2424-2431
21. Gainetdinov R.R., Fumagalli F., Wang Y.M., Jones S.R., Levey A.I., Miller G.W., and Caron M.G. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knock-out mice. J. Neurochem. 70 (1998) 1973-1978
22. Gibb J.W., Stone D.M., Johnson M., and Hanson G.R. Role of dopamine in the neurotoxicity induced by amphetamine and related designer drugs. NIDA Res. Monogr. 94 (1989) 161-178
23. Golbe L.I., and Mouradian M.M. Alpha-synuclein in Parkinson's disease: light from two new angles. Ann. Neurol. 55 (2004) 153-156
24. Greenamyre J.T., and Hastings T.G. Biomedicine. Parkinson's-divergent causes, convergent mechanisms. Science 304 (2004) 1120-1122
25. Iacovelli L., Salvatore L., Capobianco L., Picascia A., Barletta E., Storto M., Mariggio S., Sallese M., Porcellini A., Nicoletti F., and De Blasi A. Role of G protein-coupled receptor kinase 4 and b-arrestin 1 in agonist-stimulated metabotropic glutamate receptor 1 internalization and activation of mitogen-activated protein kinases. J. Biol. Chem. 278 (2003) 12433-12442
26. Jakel R.J., and Maragos W.F. Neuronal cell death in Huntington's disease: a potential role of dopamine. Trends Neurosci. 23 (2000) 239-245
27. Jones S.R., Gainetdinov R.R., Wightman R.M., and Caron M.G. Mechanism of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18 (1998) 1979-1986
28. Kalant H. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. Can. Med. Assoc. J. 165 (2001) 917-928
29. Kim S.J., Sung J.Y., Um J.W., Hattori N., Mizuno Y., Tanaka K., Paik S.R., Kim J., and Chung K.C. Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain. J. Biol. Chem. 278 (2003) 41890-41899
30. Kirik D., Annett L.E., Burger C., Muzyczka N., Mandel R.J., and Bjorklund A. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human a-synuclein: a new primate model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2884-2889
31. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutation in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
32. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., and Riess O. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18 (1998) 106-108
33. Larsen K.E., Fon E.A., Hastings T.G., Edwards R.H., and Sulzer D. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci. 22 (2002) 8951-8960
34. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., and Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature 395 (1998) 451-452
35. Macey T.A., Gurevich V.V., and Neve K.A. Preferential interaction between the dopamine D2 receptor and arrestin in neostriatal neurons. Mol. Pharmacol. 66 (2004) 1635-1642
36. McNaught K.S., Belizaire R., Isacson O., Jenner P., and Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179 (2003) 38-46
37. McNaught K.S., Perl D.P., Brownell A.L., and Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56 (2004) 149-162
38. Meredith G.E., Totterdell S., Petroske E., Santa Cruz K., Callison R.C., and Lau Y.-S. Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res. 956 (2002) 156-165
39. Miller D.B., and O'Callaghan J.P. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270 (1994) 752-760
40. Miller G.W., Gainetdinov R.R., Levey A.I., and Caron M.G. Dopamine transporter and neuronal injury. Trends Pharmacol. Sci. 20 (1999) 424-429
41. Moy L.Y., Zeevalk G.D., and Sonsalla P.K. Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures. J. Neurochem. 74 (2000) 1656-1665
42. Olanow C.W., Perl D.P., DeMartino G.N., and McNaught K.S. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol. 3 (2004) 496-503
43. Parruti G., Peracchia F., Sallese M., Ambrosini G., Masini M., Rotilio D., and De Blasi A. Molecular analysis of human β-arrestin1: cloning, tissue distribution and regulation of expression. Identification of two isoforms generated by alternative splicing. J. Biol. Chem. 268 (1993) 9753-9761
44. Petersen A., Larsen K.E., Behr G.G., Romero N., Przedborski S., Brundin P., and Sulzer D. Expanded CAG repeats in exon I of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. Hum. Mol. Genet. 10 (2001) 1243-1254
45. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
46. Quan L., Ishikawa T., Tomomi M., Li D.-R., Zhao D., Oritani S., Zhu B.-L., and Maeda H. Ubiquitin-immunoreactive in the midbrain of methamphetamine abusers. Legal Med. 7 (2005) 144-150
47. Rochet J.C., Outeiro T.F., Conway K.A., Ding T.T., Volles M.J., Lashuel H.A., Bieganski R.M., Lindquist S.L., and Lansbury P.T. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J. Mol. Neurosci. 23 (2004) 23-34
48. Schmidt C.J., Ritter J.K., Sonsalla P.K., Hanson G.R., and Gibb J.W. Role of dopamine in the neurotoxic effects of metamphetamine. J. Pharmacol. Exp. Ther. 233 (1985) 539-544
49. Seiden L.S. Methamphetamine: toxicity to dopaminergic neurons. NIDA Res. Monogr. 62 (1985) 100-116
50. Shenoy S.K., and Lefkowitz R.J. Trafficking patterns of beta-arrestin and G protein-coupled receptors determined by the kinetics of beta-arrestin deubiquitination. J. Biol. Chem. 278 (2003) 14498-14506
51. Shenoy S.K., McDonald P.H., Kohout T.A., and Lefkowitz R.J. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 294 (2001) 1307-1313
52. Sherer T.B., Kim J.H., Betarbet R., and Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179 (2003) 9-16
53. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. α-Synuclein in Lewy bodies. Nature 388 (1997) 839-840
54. Stefanis L., Larsen K.E., Rideout H.J., Sulzer D., and Greene L.A. Expression of A53T mutant but not wild-type α-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21 (2001) 9549-9560
55. Sulzer D. Alpha-synuclein and cytosolic dopamine: stabilizing a bad situation. Nat. Med. 7 (2001) 1280-1282
56. Wojcikiewicz R.J. Regulated ubiquitination of proteins in GPCR-initiated signaling pathways. Trends Pharmacol. Sci. 25 (2004) 35-41
57. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Tortosa E., del Ser T., Munoz D.G., and de Yebenes J.G. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 (2004) 164-173